USMLE Step 3 Quiz: Heart Failure Longitudinal Care

What this quiz covers

This quiz focuses on Heart Failure Longitudinal Care, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Discontinue spironolactone immediately due to acute kidney injury and hyperkalemia.
2. Reduce the spironolactone dose to 12.5 mg daily and recheck labs in one week. (correct answer)
3. Continue the current spironolactone dose and advise a low-potassium diet.
4. Discontinue lisinopril to mitigate the risk of worsening hyperkalemia.

Explanation: The correct answer is to reduce the spironolactone dose and recheck labs soon. A modest increase in creatinine (<30-35% from baseline) and mild hyperkalemia (5.1-5.5 mEq/L) are expected effects when initiating a mineralocorticoid receptor antagonist (MRA). The appropriate response is to decrease the dose, not stop the medication entirely, as MRAs provide significant mortality benefit. Discontinuing the MRA (A) is overly aggressive. Continuing the same dose (C) without close follow-up is unsafe. Discontinuing the ACE inhibitor (D) is incorrect; the MRA is the newly added agent and should be adjusted first.

Question 2

1. Providing a 30-day supply of all prescribed medications at discharge.
2. Arranging for a home health nurse to visit weekly for one month for assessment.
3. Scheduling a follow-up appointment with his primary care physician or cardiologist within 7-10 days. (correct answer)
4. Giving detailed written instructions on a 2-gram sodium and 2-liter fluid restricted diet.

Explanation: Early post-discharge follow-up (within 7-10 days) is a critical component of transitional care for heart failure patients and has the strongest evidence for reducing 30-day readmissions. This visit allows for assessment of volume status, medication adjustment, lab monitoring, and reinforcement of education. While medication access (A), home health services (B), and dietary education (D) are all valuable components of a comprehensive discharge plan, the structured, early physician follow-up is the single most impactful intervention for preventing early readmission.

Question 3

1. Referral for implantable cardioverter-defibrillator (ICD) placement only.
2. Referral for cardiac resynchronization therapy with a defibrillator (CRT-D). (correct answer)
3. Continuation of current medical therapy with re-evaluation in another 3 months.
4. Addition of ivabradine to his current regimen to further reduce heart rate.

Explanation: This patient meets all criteria for CRT-D therapy. He has an LVEF ≤35% despite ≥3 months of optimal GDMT, remains symptomatic (NYHA Class III), is in sinus rhythm, and has a LBBB with a QRS duration ≥150 ms. CRT is indicated to improve symptoms and mortality by correcting ventricular dyssynchrony. An ICD is also indicated for primary prevention of sudden cardiac death. Therefore, a combined CRT-D device is the most appropriate choice. An ICD alone (A) would be insufficient as he also qualifies for CRT. Waiting longer (C) is not indicated as he has had an adequate trial of GDMT. Ivabradine (D) could be considered if his heart rate were ≥70 bpm, but CRT-D is the primary indicated therapy given the wide QRS and LBBB.

Question 4

1. Schedule weekly outpatient intravenous diuretic infusions to manage volume.
2. Initiate discussion about goals of care and refer for advanced heart failure therapies evaluation. (correct answer)
3. Add digoxin 0.125 mg daily to improve symptoms and reduce hospitalizations.
4. Arrange for intermittent home dobutamine infusions for palliative symptom relief.

Explanation: This patient has refractory, end-stage (Stage D) heart failure. The most appropriate step is to address the overall trajectory of his illness. This involves a frank discussion about his goals of care (e.g., focus on comfort vs. life extension) and a formal referral to an advanced heart failure center to be evaluated for therapies such as left ventricular assist device (LVAD) or heart transplantation. While IV diuretics (A), digoxin (C), or home inotropes (D) might be used as palliative or bridging measures, they do not address the fundamental need for a higher level of care or shared decision-making about the patient's long-term goals.

Question 5

1. Initiate oral ferrous sulfate supplementation.
2. Administer intravenous ferric carboxymaltose. (correct answer)
3. Begin treatment with an erythropoiesis-stimulating agent.
4. Recommend transfusion of one unit of packed red blood cells.

Explanation: This patient has iron deficiency anemia (ferritin <100 ng/mL or ferritin 100-300 ng/mL with TSAT <20%), a common comorbidity in heart failure. In symptomatic HF patients with iron deficiency, intravenous iron repletion has been shown to improve symptoms, functional capacity, and quality of life. Oral iron (A) is often poorly absorbed and tolerated in HF patients due to gut edema and inflammation. Erythropoiesis-stimulating agents (C) have been associated with harm in this population and are not recommended. Transfusion (D) is reserved for acute hemodynamic instability or severe symptoms, not for chronic stable anemia at this level.

Question 6

1. Decrease the dose of sacubitril/valsartan to 24/26 mg twice daily. (correct answer)
2. Decrease the dose of metoprolol succinate to 50 mg daily.
3. Discontinue the furosemide as she is likely volume depleted.
4. Advise her to switch back to her previous ACE inhibitor or ARB.

Explanation: When a patient on an angiotensin receptor-neprilysin inhibitor (ARNI) develops symptomatic hypotension, the preferred initial strategy is often to reduce the dose of the ARNI or other vasodilating agents. Since the ARNI was the most recently adjusted medication, reducing its dose is a logical first step. Decreasing the beta-blocker (B) is another option, but ARNIs have a more potent blood pressure lowering effect. Discontinuing the diuretic (C) may be considered if there are clear signs of volume depletion, but lightheadedness is a direct effect of vasodilation. Switching back to an ACEi/ARB (D) is not necessary unless the ARNI is not tolerated even at the lowest dose, as it provides superior outcomes.

Question 7

1. Screening colonoscopy.
2. Pneumococcal vaccination (PCV20 or PCV15 followed by PPSV23).
3. Shingles (recombinant zoster) vaccination.
4. Annual influenza vaccination. (correct answer)

Explanation: When managing patients with heart failure, you must balance ongoing cardiac care with essential preventive measures. This question tests your understanding of vaccination priorities in vulnerable populations during flu season. The correct answer is D because annual influenza vaccination is critically important for patients with heart failure. Influenza can trigger acute decompensation in HFrEF patients, leading to hospitalizations and increased mortality. Since this visit occurs in October—peak flu vaccination season—this intervention takes priority. The CDC specifically recommends annual flu vaccines for all patients with cardiovascular disease as a high-priority preventive measure. Choice A is incorrect because screening colonoscopy, while important for this age group, is not time-sensitive like seasonal vaccinations and doesn't directly impact his heart failure prognosis in the immediate term. Choice B represents a valuable intervention since pneumococcal disease poses significant risks to heart failure patients, but it's not seasonal and can be administered at subsequent visits without losing efficacy. Choice C, while recommended for adults over 60, is similarly non-urgent. Zoster vaccination provides important protection but doesn't carry the same immediate seasonal timing requirements or direct cardiovascular risk implications as influenza vaccination. Remember that USMLE Step 3 often tests clinical prioritization in real-world scenarios. When you see heart failure patients during flu season, think "influenza vaccination first." The combination of increased infection risk, potential for cardiac decompensation, and seasonal timing makes this the highest-yield preventive intervention at this specific visit.

Question 8

1. Initiating a rhythm-control strategy with amiodarone.
2. Maintaining a rate-control strategy with a beta-blocker and/or digoxin.
3. Ensuring long-term anticoagulation with a direct oral anticoagulant or warfarin. (correct answer)
4. Referring for catheter ablation of atrial fibrillation.

Explanation: In patients with atrial fibrillation and heart failure, the single most important intervention to prevent major adverse events (specifically stroke) is therapeutic anticoagulation. Given her CHA₂DS₂-VASc score of 5, her risk of stroke is high, and anticoagulation is mandatory unless contraindicated. While rate control (B) is important for symptom management and preventing tachycardia-mediated cardiomyopathy, and rhythm control strategies (A, D) may be considered, neither has been consistently shown to be superior to rate control for mortality benefit, and they do not replace the need for stroke prevention with anticoagulation.

Question 9

1. Add amiodarone to suppress the NSVT and prevent future shocks.
2. Continue current management and monitoring, as the device is functioning appropriately. (correct answer)
3. Increase the dose of carvedilol to further suppress ventricular ectopy.
4. Refer the patient for an electrophysiology study and possible ablation.

Explanation: Asymptomatic, non-sustained VT that does not trigger ICD therapy does not require specific treatment. The purpose of the ICD is to treat life-threatening sustained arrhythmias, and its detection of NSVT shows it is monitoring correctly. Adding empiric amiodarone (A) is not indicated for asymptomatic NSVT and would expose the patient to significant potential toxicity. The patient is already on an optimal dose of carvedilol (C), and further increases may not be tolerated. Ablation (D) is reserved for patients with recurrent symptomatic VT or frequent ICD shocks despite medical therapy.

Question 10

1. Start a selective serotonin reuptake inhibitor (SSRI) such as sertraline.
2. Refer her to a psychiatrist for immediate management of her symptoms.
3. Reassure her that these feelings are a normal part of having a chronic illness.
4. Administer a validated screening tool for depression, such as the PHQ-9. (correct answer)

Explanation: When you encounter a patient with symptoms suggestive of depression, especially in the context of chronic illness, the first step is always objective assessment before initiating treatment. This question tests your understanding of the systematic approach to diagnosing depression in primary care. The correct approach is option D - administering a validated screening tool like the PHQ-9. This patient presents with classic depressive symptoms: anhedonia (loss of interest), hopelessness, sleep disturbance, and appetite changes lasting over a month. However, before making any therapeutic decisions, you need to establish the severity and confirm the diagnosis using standardized criteria. The PHQ-9 provides objective scoring that guides treatment decisions and establishes baseline severity for monitoring response. Option A is premature - while SSRIs like sertraline are appropriate first-line treatments for depression in heart failure patients, you shouldn't start antidepressants without first confirming the diagnosis and assessing severity. Option B represents unnecessary escalation - primary care physicians are fully capable of managing depression, and immediate psychiatric referral isn't indicated unless there are suicidal ideations or treatment-resistant cases. Option C is both dismissive and incorrect - while depression is more common in chronic illness, it's never "normal" and always warrants evaluation and treatment. For USMLE Step 3, remember that clinical decision-making questions often test your ability to follow proper diagnostic sequences. When symptoms suggest a psychiatric condition, always screen and assess objectively before treating. The pattern is: recognize symptoms → validate with screening tools → then treat based on results.

Question 11

1. Increase the furosemide dose to 120 mg twice daily.
2. Admit the patient for a continuous intravenous infusion of furosemide.
3. Switch from oral furosemide to an equivalent oral dose of bumetanide.
4. Add a thiazide-like diuretic, such as metolazone, 30 minutes before a furosemide dose. (correct answer)

Explanation: When you encounter diuretic resistance in heart failure patients, think about the nephron's anatomy and how different diuretic classes work synergistically. Loop diuretics like furosemide block sodium reabsorption in the thick ascending limb, but the distal convoluted tubule can compensate by increasing sodium retention - a phenomenon called "distal nephron hypertrophy." The most effective strategy is sequential nephron blockade using two different diuretic classes. Adding metolazone (a thiazide-like diuretic) 30-60 minutes before furosemide blocks the distal tubule's compensatory mechanism, creating dramatic synergistic diuresis. This combination is so potent it requires careful monitoring for electrolyte depletion and volume depletion. Choice A (increasing furosemide to 120 mg) hits the ceiling effect - loop diuretics have a dose-response plateau, and this patient likely needs mechanistic enhancement, not just higher doses. Choice B (continuous IV furosemide) might improve bioavailability but doesn't address the fundamental resistance mechanism and requires hospitalization. Choice C (switching to bumetanide) changes the loop diuretic but doesn't overcome the distal tubule compensation - you're still hitting the same resistance pathway. The thiazide-furosemide combination (D) addresses the core pathophysiology by blocking sodium reabsorption at two different nephron sites, preventing the kidney's adaptive response that limits single-agent therapy. Remember: In diuretic-resistant heart failure, think combination therapy before dose escalation. The synergistic effect of sequential nephron blockade often succeeds where single-agent dose increases fail, making this a cornerstone strategy in advanced heart failure management.

Question 12

1. Life-threatening angioedema. (correct answer)
2. Symptomatic hypotension.
3. Severe hyperkalemia.
4. Acute-on-chronic kidney injury.

Explanation: Concurrent use of an ACE inhibitor (lisinopril) and an ARNI (sacubitril/valsartan) is absolutely contraindicated due to a significantly increased risk of life-threatening angioedema. This is because both ACE inhibitors and neprilysin inhibitors (sacubitril) increase levels of bradykinin. A 36-hour washout period is required when switching from an ACE inhibitor to an ARNI. While hypotension (B), hyperkalemia (C), and renal injury (D) are all risks associated with these drugs, the risk of angioedema from combined therapy is the most immediate and life-threatening concern.

Question 13

1. Enrollment in a cardiac rehabilitation program.
2. Regular monitoring of her lipid panel every 3 months.
3. Strict adherence to dual antiplatelet therapy for the prescribed duration. (correct answer)
4. Titration of her metoprolol succinate to a target heart rate of 55-60 bpm.

Explanation: Following PCI with stent placement for an ACS event, strict adherence to dual antiplatelet therapy (DAPT) is the most critical intervention to prevent the catastrophic complication of stent thrombosis. While cardiac rehabilitation (A), lipid management (B), and beta-blocker titration (D) are all important components of secondary prevention, premature cessation of DAPT carries the highest immediate risk of a major adverse cardiovascular event, including myocardial infarction and death.

Question 14

1. “Based on clinical models, he likely has less than six months to live, so we should focus on comfort.”
2. “It's very difficult to predict, but we will continue to use all available treatments to keep him alive.”
3. “I understand this is a difficult time. Let’s talk about what is most important to you and your father for his quality of life now.” (correct answer)
4. “We can refer him for evaluation for a heart transplant or a mechanical circulatory support device.”

Explanation: This question assesses communication skills in the context of advanced illness. The most appropriate response is one that is empathetic and opens a discussion about goals of care, focusing on the patient's quality of life. Providing a specific timeline (A) can be inaccurate and may not be the family's primary concern. Promising to use all available treatments (B) without discussing goals can lead to burdensome, non-beneficial care. Referring for advanced therapies (D) is inappropriate given the patient's age, dementia, and severe frailty, which are contraindications.

Question 15

1. Carvedilol, due to risk of worsening hypotension.
2. Lisinopril, because it is an ACE inhibitor.
3. Empagliflozin, due to risk of euglycemic diabetic ketoacidosis. (correct answer)
4. Metformin, due to risk of lactic acidosis.

Explanation: During periods of acute illness, hospitalization, fasting, or acute kidney injury, SGLT2 inhibitors (empagliflozin) should be held due to the increased risk of euglycemic diabetic ketoacidosis (DKA). This is a critical patient safety issue. While metformin (D) should also be held in acute kidney injury due to lactic acidosis risk, the risk of euglycemic DKA is a more specific and acute concern with SGLT2 inhibitors in this 'sick day' scenario. Lisinopril (B) and carvedilol (A) are often held or dose-reduced during acute decompensation, but the risk of DKA with the SGLT2 inhibitor is a particularly dangerous and often overlooked complication.

Question 16

1. Approve ibuprofen 400 mg up to three times daily for no more than five days.
2. Prescribe a short course of celecoxib, as it is a COX-2 selective inhibitor.
3. Suggest he try naproxen instead, as it has a better cardiovascular safety profile.
4. Recommend acetaminophen as a safer first-line alternative for his pain. (correct answer)

Explanation: When managing pain in patients with heart failure with reduced ejection fraction (HFrEF), you must carefully consider how analgesics affect cardiovascular function and fluid balance. NSAIDs pose significant risks in this population due to their effects on renal function and sodium retention. Acetaminophen (Answer D) is the safest first-line analgesic for patients with HFrEF. It provides effective pain relief without the cardiovascular and renal complications associated with NSAIDs. Unlike NSAIDs, acetaminophen doesn't cause sodium retention, fluid accumulation, or worsen heart failure symptoms. Answer A (ibuprofen) is problematic because all NSAIDs, including ibuprofen, can worsen heart failure by promoting sodium and water retention, reducing the effectiveness of ACE inhibitors and diuretics, and potentially precipitating heart failure exacerbations. Even short-term use carries these risks. Answer B (celecoxib) represents a common misconception. While COX-2 selective inhibitors may have fewer GI side effects, they still carry significant cardiovascular risks and can worsen heart failure through similar mechanisms as traditional NSAIDs. The selectivity doesn't eliminate the cardiovascular concerns. Answer C (naproxen) is incorrect because naproxen actually has one of the highest cardiovascular risk profiles among NSAIDs. Recent studies suggest it may increase cardiovascular events more than other NSAIDs, making it particularly inappropriate for heart failure patients. Remember: In patients with heart failure, always consider acetaminophen first for pain management. NSAIDs of any type can destabilize carefully managed heart failure patients and should generally be avoided regardless of the clinical scenario.

Question 17

1. Prescribe a low-dose benzodiazepine to improve sleep quality.
2. Empirically initiate continuous positive airway pressure (CPAP) therapy.
3. Refer the patient for a formal polysomnography (sleep study). (correct answer)
4. Attribute his fatigue to his underlying heart failure and continue current care.

Explanation: This patient's symptoms are highly suggestive of obstructive sleep apnea (OSA), a condition that is very common in patients with heart failure and can exacerbate it. The most appropriate next step is to confirm the diagnosis with a formal sleep study (polysomnography). Prescribing sedatives like benzodiazepines (A) can worsen OSA. While CPAP (B) is the treatment for OSA, it should not be initiated empirically without a diagnostic study. Attributing the fatigue solely to HF (D) would miss an important and treatable comorbidity that impacts cardiovascular health.

Question 18

1. Adding spironolactone to her regimen.
2. Switching lisinopril to sacubitril/valsartan.
3. Adding empagliflozin to her regimen. (correct answer)
4. Adding digoxin for symptomatic improvement.

Explanation: For patients with HFpEF, SGLT2 inhibitors (such as empagliflozin or dapagliflozin) are the first class of medications to demonstrate a clear benefit in reducing the composite outcome of cardiovascular death or hospitalization for heart failure. While spironolactone (A) has shown some benefit in certain HFpEF subgroups and sacubitril/valsartan (B) has a conditional recommendation, the evidence for SGLT2 inhibitors is more robust across the spectrum of LVEF. Digoxin (D) has no proven mortality benefit in HFpEF and is not a first-line therapy.

Question 19

1. The need for frequent home blood glucose monitoring due to risk of hypoglycemia.
2. The risk of genitourinary fungal infections and the importance of perineal hygiene. (correct answer)
3. The potential for developing a persistent, dry cough within the first few months.
4. The importance of taking the medication with food to avoid gastrointestinal upset.

Explanation: The most common and important side effect to counsel patients on when starting an SGLT2 inhibitor like dapagliflozin is the increased risk of mycotic genital infections due to glycosuria. Because the patient does not have diabetes and is not on other glucose-lowering agents, the risk of hypoglycemia (A) is very low. A dry cough (C) is a characteristic side effect of ACE inhibitors, not SGLT2 inhibitors. SGLT2 inhibitors can be taken with or without food (D).

Question 20

1. Increase carvedilol to the target dose of 25 mg twice daily. (correct answer)
2. Switch lisinopril to an angiotensin receptor-neprilysin inhibitor (ARNI).
3. Add an SGLT2 inhibitor such as dapagliflozin.
4. Add ivabradine to lower her heart rate further.

Explanation: The foundational principle of HFrEF management is to titrate evidence-based medications to their target doses as tolerated. This patient is on a sub-target dose of her beta-blocker (carvedilol 12.5 mg bid, target 25 mg bid). Before adding new classes of drugs, it is essential to optimize the doses of the foundational therapies (ACEi/ARB/ARNI, beta-blocker, MRA). Her blood pressure and heart rate allow for up-titration of carvedilol. Switching to an ARNI (B) or adding an SGLT2 inhibitor (C) are appropriate steps, but typically after foundational drugs are at or near target doses. Ivabradine (D) is not indicated as her heart rate is <70 bpm and her beta-blocker is not yet at the maximum tolerated dose.